- To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy,
once every 2 weeks (with and without a loading dose at Cycle 1) to patients with
advanced solid tumors (Escalation Phase).
- To assess efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST
1.1) (Expansion Phase) when SAR408701 is administered once every 2 weeks with or without
a loading dose at Cycle 1.
- To characterize the overall safety profile of SAR408701.
- To characterize the pharmacokinetic (PK) profile of SAR408701 and of its potential
- To identify the recommended phase 2 dose (RP2D) of SAR408701.
- To assess the potential immunogenicity of SAR408701.
The study duration for an individual patient will start from the signature of the informed
consent, will include a period to assess eligibility (screening period) of up to
approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30
days following the last administration of study drug, and at least one follow-up visit after
the end-of-treatment visit. Additional follow-up visits may be required until resolution or
stabilization of adverse events (at least 30 days). Treatment may continue until precluded by
toxicity, progression, or upon patient's request. If the patient stops study treatment for
reason other than disease progression, follow-up visit will be performed every 3 months until
disease progression or initiation of another anti-tumor treatment or death, whichever comes
- Locally advanced or metastatic solid malignant tumor disease for which no standard
alternative therapy is available.
- Availability of archived tumor tissue for carcinoembryonic antigen-related cell
adhesion molecule 5 (CEACAM5 or CEA) testing.
- For participants in the Main Escalation Phase and in the Loading dose Escalation bis
cohorts : patients with tumors expressing or likely to be expressing CEACAM5 which
includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC),
gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas
adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial
ovarian cancer and endometrial adenocarcinoma are favored, or if carcinoembryonic
antigen (CEA) plasma levels >5 ng/mL.
- For participants to the Expansion Phase cohorts: patients with CRC or with CEACAM5
positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma
(including esophago-gastric junction adenocarcinoma of the Siewert types II and III).
- At least one measurable lesion by RECIST v1.1 in the Expansion Phase only.
- At least one lesion amenable to biopsy (Expansion cohort - CRC and gastric cancer
only). Patient must consent to a baseline biopsy for retrospective confirmation of
tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy.
- Signed informed consent.
- Aged less than 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status more than 1.
- New or progressing brain involvement.
- Concurrent treatment with any other anticancer therapy or inadequate wash-out period
for prior anticancer therapies before first administration of SAR408701, or
non-resolution of toxicities induced by these anticancer therapies.
- Female or male patients with reproductive potential who do not agree to use an
accepted effective method of contraception during the study treatment period and for
at least 3 months following completion of study treatment.
- Pregnancy or breast-feeding.
- Participation to any clinical research study evaluating another investigational drug
or therapy within 3 weeks of initiation of study regimen.
- Prior therapy targeting CEACAM5.
- Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates).
- Poor bone marrow reserve resulting in low blood cell counts.
- Poor kidney and liver functions.
- Any of the following within 6 months prior to study enrolment: infectious or
inflammatory bowel disease, diverticulitis, gastrointestinal perforation, intestinal
obstruction, and gastrointestinal hemorrhage. Patients with malabsorption syndrome are
- Previous history and or unresolved corneal disorders. The use of contact lenses is not
- Unresolved signs and symptoms of neuropathy; Grade 1 is acceptable if prior neurotoxic
drugs such as cisplatin or taxanes.
- Abnormal cardiac function defined by a left ventricular ejection fraction (LVEF) of
- Cardiac conduction defects, or any other clinically significant arrhythmias.
- Known intolerance to infused protein products.
- Medical conditions requiring concomitant administration of medications with narrow
therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose
reduction cannot be considered.
- Medical conditions requiring concomitant administration of strong CYP3A inhibitor,
unless it can be discontinued at least 2 weeks before 1st administration of SAR408701.
- Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid as
per package insert of each drug, including the following: increase intraocular
pressure, prior or current glaucoma, narrow-angle glaucoma, ongoing eye infection,
uncontrolled hypertension, known/suspected allergy to constituents of the preparation
(such as sodium bisulfite).
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.